What is the fair value of Cellectis SA (NASDAQ-CLLS) stock?

The current fair value estimate for Cellectis SA (NASDAQ-CLLS) is $1.72. This implies an estimated upside of 10.3% versus the current market price.

Is Cellectis SA (NASDAQ-CLLS) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 10.3% versus the current market price.

What is the analyst price target for NASDAQ-CLLS stock?

The available analyst price target for Cellectis SA (NASDAQ-CLLS) is $5.33. The analyst target implies estimated upside of 241.3%.

How is the financial health of Cellectis SA?

The current financial health read for Cellectis SA (NASDAQ-CLLS) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Cellectis SA's next earnings date?

The next earnings date currently listed for Cellectis SA (NASDAQ-CLLS) is November 9, 2026.

Does Cellectis SA (NASDAQ-CLLS) pay dividends?

The latest available data indicates no current dividend yield for Cellectis SA (NASDAQ-CLLS).

What is the market capitalization of Cellectis SA?

The current market capitalization listed for Cellectis SA is 115.8 M.

What is the enterprise value of Cellectis SA?

The current enterprise value listed for Cellectis SA is 27.58 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Cellectis SA?

The ticker symbol for Cellectis SA is NASDAQ-CLLS, and the stock is listed on NASDAQ.

Where is Cellectis SA (NASDAQ-CLLS) listed?

Cellectis SA (NASDAQ-CLLS) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Cellectis SA?

The current debt-to-total-capital ratio listed for Cellectis SA is 42.1%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Cellectis SA?

The free float listed for Cellectis SA is 66.8%. Free float helps investors understand how much of the share base is available for public trading.

Cellectis SA (CLLS) Fair Value & Stock Analysis

Cellectis SA (CLLS)

Cellectis S.A. is a clinical-stage biotechnology company focused on gene-editing-based therapies. Its research portfolio centers on allogeneic chimeric antigen receptor T-cell product candidates for immuno-oncology, along with gene therapy programs for other therapeutic areas. The company is advancing BALLI-01 to assess lasme-cel in patients with relapsed or refractory acute lymphoblastic leukemia, and NatHaLi-01 to evaluate eti-cel in relapsed or refractory B-cell non-Hodgkin’s lymphoma. Additional programs include ALPHA3 for large B-cell lymphoma, TRAVERSE for advanced or metastatic clear cell renal cell carcinoma, and a melanoma program for unresectable or metastatic disease. Cellectis was founded in 1999 and is headquartered in Paris, France. The listed security is an ADR on NASDAQ representing the company’s common stock.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-CLLS	$1.72	10.3% Upside	Fair	$5.33	241.3% Upside	Bargain	Fair	0.0%	November 9, 2026	2.8x	1.8x	115.8 M	27.58 M	42.1%	66.8%	-0.5	67.1%